Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,079 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Neoadjuvant therapy Clear all
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
64
States / cities
Dothan, Alabama • Scottsdale, Arizona • Sun City, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Early Phase 1 Interventional

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

NCT06888102
View directory record Official record
Conditions
High-risk Prostate Cancer
Interventions
Neoadjuvant Epigenetic Therapy
Drug
Lead sponsor
Edwin Posadas, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

NCT07222657
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Esophageal Cancer
Interventions
Standard of care chemotherapy, LNSC
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

NCT00706641
View directory record Official record
Conditions
Transitional Cell Carcinoma of the Bladder
Interventions
Dasatinib, Radical Cystectomy
Drug · Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Not applicable Interventional

Microneedling vs Dermabrasion for Early Facial Scar Resurfacing

NCT06171386
View directory record Official record
Conditions
Scar
Interventions
Microneedling, Dermabrasion
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting No phase listed Observational

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

NCT07226154
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Small RNA sequencing, PRECEPT assay (qRT-PCR validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional Results available

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

NCT03029611
View directory record Official record
Conditions
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

NCT04323202
View directory record Official record
Conditions
Basal Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Tissue collection
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

NCT01383928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
20
States / cities
Berkeley, California • Duarte, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 31, 2026, 2:35 PM EDT
Completed No phase listed Observational

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

NCT02370277
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 1Phase 2 Interventional

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

NCT01743157
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Biochemo + bevacizumab then ipilimumab
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Early Phase 1 Interventional

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

NCT05704283
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Ultrasound Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

NCT00520013
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Papillary Serous Mullerian Tumor, Clear Cell Mullerian Tumor
Interventions
bevacizumab, erlotinib, paclitaxel, carboplatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

NCT06441890
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
Paclitaxel, Nab-paclitaxel, Docetaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Withdrawn Phase 2 Interventional

Pilot Study for Locally Advanced Head and Neck Cancer

NCT01262859
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting No phase listed Observational

Quantitative MRI Assessment of Breast Cancer Therapy Response

NCT05704062
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
4
States / cities
Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Recruiting Phase 1 Interventional

PSMA PET Response Guided SabR in High Risk Pca

NCT06044857
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
68-Ga PSMA11
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Itraconazole in Non-small Cell Lung Cancer

NCT02357836
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Itraconazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Phase II Bevacizumab + Tax In Advanced Breast Cancer

NCT00027885
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, cyclophosphamide, docetaxel, doxorubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Cleveland, Ohio • Middleburg Heights, Ohio • Orange, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02849990
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Degarelix, Indomethacin, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 31, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 2:35 PM EDT